(4R,8S,9S,11S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (4R,8S,9S,11S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
• 化学式: C₂₅H₃₄O₆
• 分子量: 430.5
• InChiKey: VOVIALXJUBGFJZ-UEAXUQQNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  93.1
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• PROCESS FOR PREPARING BUDESONIDE
  申请人：Lenna Roberto

  公开号：US20090259037A1

  公开（公告）日：2009-10-15

  A process is described for preparing budesonide which comprises the steps of: a) preparing an aqueous hydrochloric acid solution; b) reacting 16α-hydroxyprednisolone and butyraldehyde within the solution prepared in step a), in an inert atmosphere; c) quenching the reaction of step b) with water. The process of the invention enables the ratio between the A and B epimers of budesonide to be controlled.

  一种制备布地奈德的方法被描述，包括以下步骤：a）制备水溶性盐酸溶液；b）在惰性气氛下，在步骤a）制备的溶液中反应16α-羟基泼尼松龙和丁醛；c）用水淬灭步骤b）的反应。该发明的方法使得布地奈德的A和B表异构体之间的比例得以控制。
• Process for preparing budesonide
  申请人：INDUSTRIALE CHIMICA S.r.l.

  公开号：EP2108653A1

  公开（公告）日：2009-10-14

  A process is described for preparing budesonide which comprises the steps of: a) preparing an aqueous hydrochloric acid solution; b) reacting 16α-hydroxyprednisolone and butyraldehyde within the solution prepared in step a), in an inert atmosphere; c) quenching the reaction of step b) with water. The process of the invention enables the ratio between the A and B epimers of budesonide to be controlled.

  本发明描述了一种制备布地奈德的工艺，该工艺包括以下步骤：a) 制备盐酸水溶液；b) 在惰性气氛中，在步骤 a) 中制备的溶液中，16α-羟基泼尼松龙和丁醛发生反应；c) 用水淬灭步骤 b) 中的反应。本发明的工艺可以控制布地奈德的 A 表体和 B 表体之间的比例。
• US8119793B2
  申请人：——

  公开号：US8119793B2

  公开（公告）日：2012-02-21
• [EN] ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF<br/>[FR] ANTICORPS ANTI-MSR1 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：REGENERON PHARMA

  公开号：WO2019217591A1

  公开（公告）日：2019-11-14

  Provided herein are antibodies and antigen-binding fragments that bind MSR1 and methods of use thereof. According to certain embodiments, the antibodies bind human MSR1 with high affinity. In certain embodiments, the antibodies bind MSR1 without blocking, or blocking less than 90%, of modified LDL binding to MSR1. In some embodiments, the antibodies bind cell surface expressed-MSR1 and are internalized. The antibodies of the invention may be fully human antibodies. The invention includes anti-MSR1 antibodies, or antigen-binding fragments thereof, conjugated to drugs or therapeutic compounds.